Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: garlic supplementation vs placebo

Need for antibiotics days of antibiotic use · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: garlic supplementation vs placebo

QoL · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: garlic supplementation vs placebo

Sputum microbiology · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: garlic supplementation vs placebo

Inflammatory markers · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: monoclonal antibody KB001‐A vs placebo

Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.4]
2 studies · 196 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 4.74 [0.28, 79.44]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 1.3 [0.9, 1.87]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
HR 1 [0.69, 1.45]
1 study · 169 participants
Moderate

Summary of findings: monoclonal antibody KB001‐A vs placebo

QoL · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings: β‐carotene vs placebo

FEV1 % predicted · adults and children with cystic fibrosis

Summary of findings: β‐carotene showed no clear difference in respiratory function absolute FEV1 % predicted compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 196 participants
Very low

Summary of findings: nitric oxide vs placebo

Pulmonary exacerbations · children (12 or over) and young adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: nitric oxide vs placebo

FEV1 (% predicted): mean change from baseline · children (12 or over) and young adults with cystic fibrosis

Summary of findings: nitric oxide showed no clear difference in respiratory function mean change in FEV1 % predicted from baseline compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Low

Summary of findings: nitric oxide vs placebo

Adverse events · children (12 or over) and young adults with cystic fibrosis

It is very uncertain whether summary of findings: nitric oxide changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 30 participants
Very low

Summary of findings: nitric oxide vs placebo

Need for antibiotics · children (12 or over) and young adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: nitric oxide vs placebo

QoL · children (12 or over) and young adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: nitric oxide vs placebo

Sputum microbiology · children (12 or over) and young adults with cystic fibrosis

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 30 participants
Very low

Summary of findings: nitric oxide vs placebo

Inflammatory markers · children (12 or over) and young adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Pulmonary exacerbations number of participants requiring IV antibiotics · children with cystic fibrosis

Summary of findings: Zinc supplementation showed no clear difference in pulmonary exacerbations number of participants requiring IV… compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 1.85 [0.65, 5.26]
1 study · 37 participants
Moderate